“And you’re ugly too” | genomeboy
"All of this, of course, was precipitated by AMP v. USPTO (“The Myriad Case”),
in which patients with family histories of breast cancer asserted that
they have not been able to get confirmatory or “second opinion” testing
because there is but a single, exclusive licensee of the patents on the most clinically important genes that predispose to hereditary breast and ovarian cancer, BRCA1 and BRCA2.
I attended the public hearing at the USPTO
in Alexandria, VA on 16 February 2012. I was so appalled by what I
heard that I attended the second one in San Diego on 9 March 2012 and
testified. I am still adding links to my testimony in order to submit it
before public comment closes on 26 March 2012. Here is a brief excerpt
on Myriad’s unwillingness to share its mutation data:................"
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.